Cross-sector approaches to levelling up health disparities with Jonathan Marron, Director General, OHID, DHSC
Author WIG Date 10 May 2023
We are delighted to welcome Jonathan Marron, Director General for the Office for Health Improvement and Disparities (OHID), Susan Rienow, Managing Director, Pfizer, Naser Turabi, Director of Evidence & Implementation at Cancer Research UK and Dr Molly Morgan Jones, Director of Policy, The British Academy.
Overcoming health inequalities across the UK is a central facet of the government’s levelling up agenda. Since its formation in October 2021, the Office for Health Improvement and Disparities (OHID) has been tasked with improving the nation’s health and breaking the link between background and prospects for a healthy life.
WIG is delighted to host this extended workshop session, featuring a keynote from Jonathan Marron, Director General for OHID at the Department for Health and Social Care, along with an expert panel.
Join us for your opportunity to:
- Learn more about OHID’s latest organisational priorities, and opportunities to work together on innovative and targeted interventions to support areas and communities experiencing the greatest disparities
- Explore how OHID is working with partners across central government, the healthcare system, local government and industry to shift healthcare focus towards prevention
- Discuss how organisations across the sectors can collaborate on analysis and evidence to identify and address the UK’s evolving healthcare challenges
To access this resource you must be a WIG member and logged in to our website.
You can register or log-in here.
Speakers at the Event
Jonathan Marron is the Director General for the Office for Health Improvement and Disparities at the Department of Health and Social Care (DHSC). Prior to this role, Jonathan was Director General of Public Health in the department. He has had a range of roles across the health service including:
- Director General for Prevention, Community and Social Care
- Director for primary, community, mental health and 7-day services at DHSC
- Director of Strategy and and Transition Director at Public Health England
- Director of Strategy and Planning at NHS South West Essex PCT
- Policy Director at Monitor
- System Reform and Commissioning Lead at DHSC
Susan is Managing Director and Country President for Pfizer in the UK, leading the organisation’s work to deliver breakthroughs that change patients’ lives across the breadth of Pfizer’s innovative medicines and vaccines portfolio.
Before taking on this role, Susan led the company’s UK Vaccines business unit during the COVID-19 pandemic, and before that the UK Hospital business unit and Essential Health division.
In March 2023, Susan was confirmed as the next President of the ABPI (The Association of the British Pharmaceutical Industry), the industry body which exists to make the UK the best place in the world to research, develop and use new medicines and vaccines. Susan will formally take up this role following the ABPI’s Annual General Meeting (AGM) in May.
Prior to her appointment as the incoming ABPI President, Susan served as ABPI Vice President, having previously represented Pfizer on the Board as both a full and co-opted member in addition to co-chairing the ABPI’s Vaccine Group. Susan is also active within other cross-industry fora and sits on the CBI President’s Committee and Health Council.
Susan has been at Pfizer for two decades, with experience across multiple global markets including in the US, Asia, and Europe, before moving to the UK in 2015.
Naser Is Director of Evidence and Implementation at Cancer Research UK, where he leads the Strategic Evidence, Cancer Intelligence, Social and Behavioural Research, and Health Systems Engagement teams. His role is to accelerate the adoption of innovation and reduce inequalities in access to best practice care. He joined CRUK from North Central London Cancer Alliance where he was Managing Director. Previously he held a number of management roles in the NHS covering strategy, operations and transformation. He started his career in social research and public sector consultancy.
Dr Molly Morgan Jones was appointed in 2018. She was previously senior research leader with RAND Europe, an independent not-for-profit research institute whose mission is to help improve policy and decision making through research and analysis. Prior to joining RAND Europe, Molly worked for the UK Department for Environment, Food and Rural Affairs (Defra) and for the U.S. Food and Drug Administration (FDA). She received her DPhil in Science and Technology Policy from the University of Sussex and has a BA in biology from Northwestern University (Illinois), United States.